GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pro-Dex Inc (NAS:PDEX) » Definitions » Sloan Ratio %

Pro-Dex (Pro-Dex) Sloan Ratio % : 6.29% (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Pro-Dex Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Pro-Dex's Sloan Ratio for the quarter that ended in Dec. 2023 was 6.29%.

As of Dec. 2023, Pro-Dex has a Sloan Ratio of 6.29%, indicating the company is in the safe zone and there is no funny business with accruals.


Pro-Dex Sloan Ratio % Historical Data

The historical data trend for Pro-Dex's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pro-Dex Sloan Ratio % Chart

Pro-Dex Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.01 11.10 29.66 13.55 4.82

Pro-Dex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.99 17.38 8.68 10.52 6.29

Competitive Comparison of Pro-Dex's Sloan Ratio %

For the Medical Instruments & Supplies subindustry, Pro-Dex's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pro-Dex's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pro-Dex's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Pro-Dex's Sloan Ratio % falls into.



Pro-Dex Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Pro-Dex's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (A: Jun. 2023 )-Cash Flow from Operations (A: Jun. 2023 )
-Cash Flow from Investing (A: Jun. 2023 ))/Total Assets (A: Jun. 2023 )
=(7.074-5.462
--0.885)/51.823
=4.82%

Pro-Dex's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(5.004-4.067
--2.296)/51.427
=6.29%

Pro-Dex's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 1.313 (Mar. 2023 ) + 3.806 (Jun. 2023 ) + -0.615 (Sep. 2023 ) + 0.5 (Dec. 2023 ) = $5.00 Mil.
Pro-Dex's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 2.338 (Mar. 2023 ) + 0.627 (Jun. 2023 ) + 0.392 (Sep. 2023 ) + 0.71 (Dec. 2023 ) = $4.07 Mil.
Pro-Dex's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -0.135 (Mar. 2023 ) + -0.152 (Jun. 2023 ) + -0.126 (Sep. 2023 ) + -1.883 (Dec. 2023 ) = $-2.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pro-Dex  (NAS:PDEX) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Pro-Dex has a Sloan Ratio of 6.29%, indicating the company is in the safe zone and there is no funny business with accruals.


Pro-Dex Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Pro-Dex's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pro-Dex (Pro-Dex) Business Description

Traded in Other Exchanges
Address
2361 McGaw Avenue, Irvine, CA, USA, 92614
Pro-Dex Inc is engaged in designing, developing, and manufacturing powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. In addition, the company provides engineering consulting and placement services, as well as quality and regulatory consulting services. Most of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
Executives
Angelita Rebamontan Domingo director 1431 MADISON ST., TUSTIN CA 92782
Van Kirk Richard Lee Jr director, officer: Chief Executive Officer 34 DEER CREEK, IRVINE CA 92604
Philp Katrina Marie Kramer director 5501 NANTUCKET PL, MINNETONKA MN 55345
Farrell William James Iii director 20200 COTTAGEWOOD RD, DEEPHAVEN MN 55331
Peter O. Haeg 10 percent owner 12701 WHITEWATER DR, SUITE 190, MINNETONKA MN 55343
Alisha Charlton officer: Chief Financial Officer 25541 COMMERCENTRE DRIVE, LAKE FOREST CA 92630
Nicholas John Swenson 10 percent owner 5000 WEST 36TH STREET, SUITE 130, MINNEAPOLIS MN 55416
Raymond E Cabillot director 3033 EXCELSIOR BLVD., STE 560, MINNEAPOLIS MN 55416
David Hovda director
Farnam Street Partners Lp /mn 10 percent owner 3033 EXCELSIOR BOULEVARD, MINNEAPOLIS, MINNEAPOLIS MN 55416
Ao Partners I, Lp 10 percent owner 5000 WEST 36TH STREET, SUITE 130, MINNEAPOLIS MN 55416
David Holder director 1052 CHARWOOD LANE, SANTA ANA CA 92705
William L Healey director 101 BULLITT LANE, STE 450, LOUISVILLE KY 40222
Michael J Berthelot director P O BOX 7277, RANCHO SANTA FE CA 92067
George J Isaac director 36 WHISPER DRIVE, WORCESTER MA 01609